Clinical Trial

Human Embryonic Stem Cell-Derived Cardiomyocyte Therapy for Chronic Ischemic Left Ventricular Dysfunction

Study acronym: HECTOR
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This clinical study will utilize a new cell therapy approach (Human embryonic stem cells derived cardiomyocytes or hESC-CMs) to improve survival and cardiac function in patients with chronic left ventricular dysfunction secondary to MI (Myocardial Infarction).
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2021-09-24; most recent amendment 2025-09-25.
Status change: Not Yet Recruiting → Recruiting 2022-09-15
Trial Details
NCT Number NCT05068674
Lead Sponsor Joseph C. Wu
Collaborators: California Institute for Regenerative Medicine (CIRM)
Conditions Chronic Ischemic Left Ventricular Dysfunction
Enrollment 18 participants
Start Date 2022-03-22
Primary Completion 2028-10 (estimated)
Study Completion 2028-10 (estimated)
Updated on ClinicalTrials.gov 2025-09-29